PDF herunterladen
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2023; 83(06): 664-672
DOI: 10.1055/a-2074-0125
GebFra Science
Review

Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer

Artikel in mehreren Sprachen: English | deutsch
Michael P. Lux
1   Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Paderborn, Germany
,
Andreas D. Hartkopf
2   Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany (Ringgold ID: RIN27197)
,
Tanja N. Fehm
3   Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany
,
Manfred Welslau
4   Onkologie Aschaffenburg, Aschaffenburg, Germany
,
Volkmar Müller
5   Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany
,
Florian Schütz
6   Gynäkologie und Geburtshilfe, Diakonissen-Stiftungs-Krankenhaus Speyer, Speyer, Germany (Ringgold ID: RIN123168)
,
Peter A. Fasching
7   Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany (Ringgold ID: RIN207200)
,
Wolfgang Janni
2   Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany (Ringgold ID: RIN27197)
,
Isabell Witzel
8   Klinik für Gynäkologie, Universitätsspital Zürich, Zürich, Switzerland (Ringgold ID: RIN31005)
,
Christoph Thomssen
9   Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany (Ringgold ID: RIN9176)
,
Milena Beierlein
7   Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany (Ringgold ID: RIN207200)
,
Erik Belleville
10   ClinSol GmbH & Co KG, Würzburg, Germany
,
Michael Untch
11   Clinic for Gynecology and Obstetrics, Breast Cancer Center, Gynecologic Oncology Center, Helios Klinikum Berlin Buch, Berlin, Germany (Ringgold ID: RIN62473)
,
Marc Thill
12   Department of Gynecology and Gynecological Oncology, Agaplesion Markus Krankenhaus, Frankfurt am Main, Germany (Ringgold ID: RIN84491)
,
Hans Tesch
13   Oncology Practice at Bethanien Hospital, Frankfurt am Main, Germany
,
Nina Ditsch
14   Department of Gynecology and Obstetrics, University Hospital Augsburg, Augsburg, Germany (Ringgold ID: RIN39694)
,
Bahriye Aktas
15   Department of Gynecology, University of Leipzig Medical Center, Leipzig, Germany
,
Maggie Banys-Paluchowski
16   Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
,
Cornelia Kolberg-Liedtke
17   Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany (Ringgold ID: RIN39081)
,
Achim Wöckel
18   Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany
,
Hans-Christian Kolberg
19   Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany
,
Nadia Harbeck
20   Breast Center, Department of Gynecology and Obstetrics and CCC Munich LMU, LMU University Hospital, München, Germany
,
Rupert Bartsch
21   Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria
,
Andreas Schneeweiss
22   National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany
,
Johannes Ettl
23   Klinik für Frauenheilkunde und Gynäkologie, Klinikum Kempten, Klinikverbund Allgäu, Kempten, Germany
,
Rachel Würstlein
20   Breast Center, Department of Gynecology and Obstetrics and CCC Munich LMU, LMU University Hospital, München, Germany
,
David Krug
24   Klinik für Strahlentherapie, Universitätsklinkum Schleswig-Holstein, Campus Kiel, Kiel, Germany (Ringgold ID: RIN15056)
,
Florin-Andrei Taran
25   Department of Gynecology and Obstetrics, University Hospital Freiburg, Freiburg, Germany
,
Diana Lüftner
26   Medical University of Brandenburg Theodor-Fontane, Immanuel Hospital Märkische Schweiz, Buckow, Germany
,
Elmar Stickeler
27   Department of Obstetrics and Gynecology, Center for Integrated Oncology (CIO Aachen, Bonn, Cologne, Düsseldorf), University Hospital of RWTH Aachen, Aachen, Germany
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

In recent years, a number of new therapies have led to advances in the treatment of patients with advanced breast carcinoma. These substances are mainly CDK4/6 inhibitors and other substances that can overcome endocrine resistance, oral selective estrogen receptor degraders, antibody drug conjugates (ADCs), and PARP inhibitors. This review summarizes and evaluates the latest study results that have been published in recent months. This includes the overall survival data of the Destiny-Breast03 study, the first analysis of the CAPItello-291 study, the comparison of CDK4/6 inhibitor treatment with chemotherapy in the first line of therapy (RIGHT Choice study), the first analysis of the Destiny-Breast02 study in the treatment setting after T-DM1 treatment, and the first analysis of the Serena-2 study.

Most of these studies have the potential to significantly change the therapeutic landscape for patients with advanced breast carcinoma and show that the continued rapid development of new therapies is always producing new results.

Keywords

breast cancer - metastatic - endocrine therapy - antibody drug conjugate - chemotherapy


Publikationsverlauf

Eingereicht: 13. April 2023

Angenommen: 14. April 2023

Artikel online veröffentlicht:
06. Juni 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References/Literatur

  • 1 Ditsch N, Kolberg-Liedtke C, Friedrich M. et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. Breast Care (Basel) 2021; 16: 214-227 DOI: 10.1159/000516419.
    CrossrefPubMedGoogle Scholar
  • 2 Cardoso F, Paluch-Shimon S, Senkus E. et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 2020; 31: 1623-1649 DOI: 10.1016/j.annonc.2020.09.010. (PMID: 32979513)
    CrossrefPubMedGoogle Scholar
  • 3 Schneeweiss A, Ettl J, Luftner D. et al. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer – Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast 2020; 54: 88-95 DOI: 10.1016/j.breast.2020.08.011.
    CrossrefPubMedGoogle Scholar
  • 4 Hartkopf AD, Huober J, Volz B. et al. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors – Data from the German PRAEGNANT breast cancer registry. Breast 2018; 37: 42-51 DOI: 10.1016/j.breast.2017.10.002.
    CrossrefPubMedGoogle Scholar
  • 5 Lobbezoo DJ, van Kampen RJ, Voogd AC. et al. In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. Ann Oncol 2016; 27: 256-262 DOI: 10.1093/annonc/mdv544.
    CrossrefPubMedGoogle Scholar
  • 6 Engler T, Fasching PA, Luftner D. et al. Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT. Geburtshilfe Frauenheilkd 2022; 82: 1055-1067 DOI: 10.1055/a-1880-0087.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 7 Jackisch C, Brucker C, Decker T. et al. Abstract P4–01–01: RIBANNA 5th interim analysis: Matched-pair analysis of progression-free survival (PFS) across treatment cohorts and comparison of frontline ribociclib + endocrine therapy PFS data from RIBANNA vs MONALEESA trials, in HR+, HER2– ABC. San Antonio Breast Cancer Symposium 2022. Cancer Res 2023; 83 (Suppl. 5) P4–01–01 DOI: 10.1158/1538-7445.SABCS22-P4-01-01.
    CrossrefPubMedGoogle Scholar
  • 8 Lu YS, Bin Mohd Mahidin EI, Azim H. et al. Abstract GS1–10: Primary Results From the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2− Advanced Breast Cancer Treated With Ribociclib + Endocrine Therapy vs Physician’s Choice Combination Chemotherapy. San Antonio Breast Cancer Symposium 2022. Cancer Res 2023; 83 (Suppl. 5) GS1–10 DOI: 10.1158/1538-7445.SABCS22-GS1-10.
    CrossrefPubMedGoogle Scholar
  • 9 Rugo HS, Bardia A, Marmé F. et al. Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2−) advanced breast cancer. J Clin Oncol 2022; 40: LBA1001 DOI: 10.1200/JCO.2022.40.17_suppl.LBA1001.
    CrossrefPubMedGoogle Scholar
  • 10 Modi S, Saura C, Yamashita T. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med 2020; 382: 610-621 DOI: 10.1056/NEJMoa1914510. (PMID: 31825192)
    CrossrefPubMedGoogle Scholar
  • 11 Hurvitz SA, Tolaney SM, Punie K. et al. Abstract GS3–06: Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. San Antonio Breast Cancer Symposium 2020. Cancer Res 2021; 81 (Suppl. 4) GS3–06 DOI: 10.1158/1538-7445.SABCS20-GS3-06.
    CrossrefPubMedGoogle Scholar
  • 12 Rugo HS, Bardia A, Marmé F. et al. Abstract GS1–11: Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC): Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients (Pts) With HR+/HER2– Metastatic Breast Cancer (mBC). San Antonio Breast Cancer Symposium 2022. Cancer Res 2023; 83 (Suppl. 5) GS1–11 DOI: 10.1158/1538-7445.SABCS22-GS1-11.
    CrossrefPubMedGoogle Scholar
  • 13 Bidard FC, Kaklamani VG, Neven P. et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol 2022; 40: 3246-3256 DOI: 10.1200/JCO.22.00338.
    CrossrefPubMedGoogle Scholar
  • 14 Bardia A, Neven P, Streich G. et al. Abstract GS2–02: Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2− advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial. San Antonio Breast Cancer Symposium 2021. Cancer Res 2022; 82 (Suppl. 4) GS2–02 DOI: 10.1158/1538-7445.SABCS21-GS2-02.
    CrossrefPubMedGoogle Scholar
  • 15 Tolaney SM, Chan A, Petrakova K. et al. AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC). Ann Oncol 2022; 33 (Suppl. 7) S80-S121 DOI: 10.1016/annonc/annonc1089.
    CrossrefPubMedGoogle Scholar
  • 16 Jimenez MM, Lim E, Gregor MCM. et al. Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study. Ann Oncol 2022; 33 (Suppl. 7) S808-S869 DOI: 10.1016/annonc/annonc1089.
    CrossrefPubMedGoogle Scholar
  • 17 Luftner D, Lux MP, Fehm TN. et al. Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer. Geburtshilfe Frauenheilkd 2023; 83: 299-309 DOI: 10.1055/a-2018-9184. (PMID: 35903715)
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 18 Aktas B, Fehm TN, Welslau M. et al. Update Breast Cancer 2022 Part 4 – Advanced-Stage Breast Cancer. Geburtshilfe Frauenheilkd 2022; 82: 922-931 DOI: 10.1055/a-1912-7362. (PMID: 35903715)
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 19 U.S. Department of Health and Human Services Food and Drug Administration (FDA). Highlights of Prescribing Information Orserdu. 2023 Zugriff am 11. April 2023 unter: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf
    PubMedGoogle Scholar
  • 20 Oliveira M, Pominchuck D, Nowecki Z. et al. Abstract GS3–02: GS3–02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial. Cancer Res 2023; 83: GS3-02 DOI: 10.1158/1538-7445.Sabcs22-gs3-02.
    CrossrefPubMedGoogle Scholar
  • 21 clinicaltrials.gov. Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (SERENA-6). 2021 Zugriff am 24. Oktober 2021 unter: https://clinicaltrials.gov/ct2/show/NCT04964934
    PubMedGoogle Scholar
  • 22 Snyder LB, Flanagan JJ, Qian Y. et al. Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer. Cancer Res 2021; 81: 44 DOI: 10.1158/1538-7445.Am2021-44.
    CrossrefPubMedGoogle Scholar
  • 23 Schott AF, Hurvitz S, Ma C. et al. Abstract GS3–03: GS3–03 ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study. Cancer Res 2023; 83: GS3–03 DOI: 10.1158/1538-7445.Sabcs22-gs3-03.
    CrossrefPubMedGoogle Scholar
  • 24 Fasching PA, Clifton K, Katashvili Z. et al. 154TiP TACTIVE-N: Open-label, randomized, noncomparative neoadjuvant phase 2 study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, or anastrozole in postmenopausal women with ER+/human epidermal growth factor receptor 2 (HER2)- localized breast cancer. ESMO Open 2023; 8 (Suppl. 4) 101493 DOI: 10.1016/j.esmoop.2023.101493.
    CrossrefPubMedGoogle Scholar
  • 25 Clinicaltrials.gov. A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery. 2023 Zugriff am 11. April 2023 unter: https://clinicaltrials.gov/ct2/show/NCT05549505
    PubMedGoogle Scholar
  • 26 Clinicaltrials.gov. ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer. 2023 Zugriff am 11. April 2023 unter: https://clinicaltrials.gov/ct2/show/NCT05501769
    PubMedGoogle Scholar
  • 27 Turner N, Oliveira M, Howell SJ. et al. Abstract GS3–04: GS3–04 Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial. Cancer Res 2023; 83: GS3–04 DOI: 10.1158/1538-7445.Sabcs22-gs3-04.
    CrossrefPubMedGoogle Scholar
  • 28 Alves CL, Ditzel HJ. Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer. Int J Mol Sci 2023; 24: 4522 DOI: 10.3390/ijms24054522. (PMID: 36901954)
    CrossrefPubMedGoogle Scholar
  • 29 Howell SJ, Casbard A, Carucci M. et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol 2022; 23: 851-864 DOI: 10.1016/S1470-2045(22)00284-4.
    CrossrefPubMedGoogle Scholar
  • 30 Cortes J, Kim SB, Chung WP. et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med 2022; 386: 1143-1154 DOI: 10.1056/NEJMoa2115022. (PMID: 35320644)
    CrossrefPubMedGoogle Scholar
  • 31 Hurvitz S, Hegg R, Chung W-P. et al. Abstract GS2–02: GS2–02 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03. Cancer Res 2023; 83: GS2-02 DOI: 10.1158/1538-7445.Sabcs22-gs2-02.
    CrossrefPubMedGoogle Scholar
  • 32 Hurvitz SA, Hegg R, Chung WP. et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 2023; 401: 105-117 DOI: 10.1016/S0140-6736(22)02420-5.
    CrossrefPubMedGoogle Scholar
  • 33 Krop I, Park YH, Kim S-B. et al. Abstract GS2–01: GS2–01 Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02. Cancer Res 2023; 83: GS2–01 DOI: 10.1158/1538-7445.Sabcs22-gs2-01.
    CrossrefPubMedGoogle Scholar
  • 34 clinicaltrials.gov. Comprehensive Analysis of Spatial, Temporal and Molecular Patters of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients (CAPTOR-BC). 2022 Zugriff am 16. Juli 2022 unter: https://clinicaltrials.gov/ct2/show/NCT05452213
    PubMedGoogle Scholar
  • 35 Fasching PA. CAPTOR-BC: Gemeinsam Forschen für eine individualisierte Ribociclib-Therapie. Senologiekongress 2022. 2022 Zugriff am 26. Juni 2022 unter: https://www.senologiekongress.de/xconfig/upload/files/Programme/Seno2022_Programm.pdf
    PubMedGoogle Scholar
  • 36 clinicaltrials.gov. Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management (MINERVA). 2022 Zugriff am 26. Juni 2022 unter: https://clinicaltrials.gov/ct2/show/NCT05362760
    PubMedGoogle Scholar